Profile data is unavailable for this security.
About the company
Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in manufacturing of pharmaceutical preparations. The Company is involved in research and development innovations, production and commercialization of life-saving vaccines based on viral vectors for the delivery of antigens targeting infectious diseases. Bavarian Nordic A/S offers travel health products including cholera, rabies, tick-borne encephalitis and typhoid vaccines, as well as vaccines sold and distributed in selected markets on behalf of third parties. The Company deals with vaccines aimed at improving public health and preparedness. Bavarian Nordic A/S focuses on vaccine solutions that help address the threat of infectious diseases. The Company operates worldwide.
- Revenue in DKK (TTM)6.64bn
- Net income in DKK984.37m
- Incorporated1992
- Employees1.38k
- LocationBavarian Nordic A/SPhilip Heymans Alle 3HELLERUP 2900DenmarkDNK
- Websitehttps://www.bavarian-nordic.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Swedencare AB (publ) | 1.54bn | 45.67m | 5.38bn | 552.00 | 117.88 | 1.09 | 21.98 | 3.49 | 0.4505 | 0.4505 | 15.21 | 48.80 | 0.2412 | 2.35 | 9.52 | 4,966,461.00 | 0.7144 | 1.38 | 0.7361 | 1.43 | 55.64 | 55.34 | 2.96 | 5.10 | 1.82 | 2.21 | 0.1746 | 45.33 | 27.48 | 88.16 | -37.96 | 20.24 | 30.90 | -- |
| Calliditas Therapeutics AB | 837.34m | -335.20m | 7.89bn | 219.00 | -- | 92.11 | -- | 9.43 | -9.78 | -9.78 | 24.43 | 2.24 | 0.7541 | 3.16 | 8.97 | 6,723,169.00 | -30.19 | -26.46 | -38.05 | -30.27 | 95.01 | -- | -40.03 | -76.59 | 2.62 | -3.99 | 0.8943 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
| BioGaia AB | 874.62m | 256.57m | 7.95bn | 220.00 | 32.15 | 8.20 | 29.21 | 9.09 | 3.98 | 3.98 | 13.56 | 15.60 | 0.6749 | -- | -- | 6,520,886.00 | 19.80 | 15.47 | 22.19 | 16.93 | 73.84 | 73.30 | 29.34 | 27.70 | -- | -- | 0.00 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
| Vimian Group AB | 2.50bn | 59.22m | 11.43bn | 1.10k | 173.80 | 2.58 | 36.64 | 4.57 | 0.1992 | 0.1992 | 8.35 | 13.40 | 0.3354 | 2.83 | 5.69 | 3,556,942.00 | 0.867 | -- | 1.01 | -- | 47.48 | -- | 2.59 | -- | 1.19 | 2.81 | 0.3729 | -- | 17.92 | -- | 245.95 | -- | -- | -- |
| Bonesupport Holding AB | 469.54m | 184.44m | 12.55bn | 127.00 | 68.31 | 31.68 | 65.65 | 26.73 | 4.38 | 4.38 | 11.13 | 9.44 | 1.30 | 0.6001 | 4.88 | 7,001,534.00 | 51.17 | -9.08 | 62.05 | -11.28 | 92.22 | 90.25 | 39.28 | -11.65 | 3.07 | -- | 0.0239 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
| Bavarian Nordic A/S | 6.64bn | 984.37m | 14.90bn | 1.38k | 14.83 | 1.46 | 9.45 | 2.24 | 12.86 | 12.86 | 86.59 | 130.35 | 0.4956 | 1.74 | 9.32 | 4,816,359.00 | 7.35 | 1.21 | 8.92 | 1.48 | 60.90 | 53.72 | 14.82 | 4.06 | 1.03 | -- | 0.0427 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
| Camurus AB | 1.02bn | 142.59m | 24.72bn | 228.00 | 174.01 | 13.22 | 162.57 | 24.29 | 3.79 | 3.79 | 27.51 | 49.94 | 0.6122 | 1.09 | 4.86 | 7,480,770.00 | 8.58 | -1.13 | 10.10 | -1.41 | 92.01 | 90.05 | 14.01 | -1.63 | 7.11 | -- | 0.0071 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
| ALK-Abello A/S | 4.94bn | 555.00m | 30.95bn | 2.83k | 61.31 | 7.21 | 36.33 | 6.26 | 2.49 | 2.49 | 21.93 | 21.19 | 0.752 | 1.29 | 5.81 | 1,749,646.00 | 8.45 | 3.50 | 10.36 | 4.37 | 63.25 | 60.66 | 11.23 | 5.07 | 1.23 | 50.27 | 0.0995 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
| Orion Oyj | 9.11bn | 1.62bn | 42.48bn | 3.70k | 26.05 | 8.00 | 21.55 | 4.66 | 1.55 | 1.55 | 8.71 | 5.04 | 0.8866 | 1.57 | 6.01 | 336,013.20 | 15.73 | 19.47 | 21.38 | 24.16 | 55.10 | 59.38 | 17.74 | 20.71 | 1.00 | 74.43 | 0.2157 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
| Swedish Orphan Biovitrum AB (publ) | 15.14bn | 1.37bn | 66.18bn | 1.77k | 47.69 | 2.76 | 17.75 | 4.37 | 6.13 | 6.13 | 69.42 | 106.08 | 0.3184 | 1.35 | 5.14 | 13,379,800.00 | 2.88 | 5.93 | 3.74 | 7.60 | 77.70 | 77.42 | 9.04 | 16.61 | 0.4918 | 3.07 | 0.3199 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
Data as of Jul 25 2024. Currency figures normalised to Bavarian Nordic A/S's reporting currency: Danish Krone DKK
21.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ATP Arbejdsmarkedets Till�gspensionas of 31 Dec 2022 | 7.16m | 9.16% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 2.29m | 2.94% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.64m | 2.10% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 1.49m | 1.90% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 1.10m | 1.41% |
| Nykredit Bank A/S (Investment Management)as of 30 Jun 2024 | 910.84k | 1.17% |
| Handelsbanken Fonder ABas of 30 Jun 2024 | 827.57k | 1.06% |
| Oddo BHF Asset Management SASas of 28 Jun 2024 | 537.59k | 0.69% |
| Victory Capital Management, Inc. (Investment Management)as of 31 Mar 2024 | 500.47k | 0.64% |
| AllianceBernstein Ltd.as of 31 Mar 2024 | 334.88k | 0.43% |
More ▼
Data from 31 Dec 2023 - 17 Jul 2024Source: FactSet Research Systems Inc.
